Myelodysplastic neoplasm with biallelic TP53 inactivation

Bone marrow is the tissue inside bones that makes blood. In a myelodysplastic neoplasm the marrow keeps working — often working hard — but the cells it produces are faulty and half-finished, and most of them are destroyed in the marrow or shortly after reaching the bloodstream. The result is a busy factory and an empty blood count.

“Dysplasia” is the word for how those cells look down a microscope: misshapen and immature. It describes appearance, not danger.

The 2022 WHO classification renamed these from “myelodysplastic syndromes” to “myelodysplastic neoplasms”. The abbreviation MDS did not change. The rename matters, because a neoplasm is a cancer in its own right — these are not a waiting room for one.

TP53 is a tumour-suppressor gene — a brake that stops damaged cells from dividing. Most people have two working copies. In this subtype both have been knocked out, which is what “biallelic” means. That can be two separate mutations, or one mutation together with the loss of the region of chromosome 17 where the other copy sits.

The underlying event is a change acquired in a single blood-forming stem cell during a person’s life. It is not inherited from a parent and it cannot be passed to anyone.

For most people no cause is ever identified. That is the most important sentence in this section, and it comes first for a reason — people look hard for something they could have done differently.

Recognised risk factors do exist: previous chemotherapy or radiotherapy for another cancer, exposure to tobacco smoke, pesticides, and solvents such as benzene, some heavy metals, and increasing age. Age is the dominant one.

Nothing in the sources we read supports a lifestyle, diet, stress or emotional cause.

The immediate harm is a shortage of working blood cells. Too few red cells brings fatigue, breathlessness and pallor. Too few neutrophils brings repeated or severe infections. Too few platelets brings easy bruising, bleeding, and pinpoint red spots under the skin.

There are two separate dangers here and it helps to keep them apart. One is the shortage itself, which can be disabling or dangerous on its own. The other is transformation into acute myeloid leukemia. Many people are harmed by the first without ever reaching the second.

That transformation is conventionally marked at 20% blasts — the youngest, most immature cells in the marrow. It is a classification boundary rather than a moment a person feels.

Losing both copies of TP53 removes a brake, and the EBMT Handbook records that it confers a higher risk of transition to acute myeloid leukemia. This is the most aggressive of the four subtypes in this library and the page is not going to soften that.

Treatment follows the higher-risk pathway. The main drug options are the hypomethylating agents azacitidine and decitabine, which strip chemical “off switches” from the DNA of abnormal cells. They are first-line for people with higher-risk MDS who are not fit for a transplant, and they control the disease rather than beating it.

The two are not equivalent. For azacitidine in higher-risk disease the NCI reports median overall survival of 24 months against 16, and two-year survival of 51% against 26%. Two randomised trials of decitabine against supportive care did not show a survival benefit.

A transplant using another person’s blood-forming cells is described by the NCI as the only potentially curative treatment for MDS, and the EBMT Handbook calls it the treatment of choice for higher-risk disease in people fit enough to be considered.

For this subtype specifically, the Handbook goes a step further and recommends preventive or pre-emptive treatment AFTER a transplant in cases with biallelic TP53 inactivation or complex chromosome findings. That is worth reading carefully: it means a transplant here is frequently the middle of the treatment rather than the end of it.

Clinical trials are a standard option across every risk level for MDS, and are particularly worth asking about for this subtype.

The route into this diagnosis is often a genetic result rather than a change in how someone feels. Because this category overrides the others, a person can be told their subtype has changed — and their classification move to the highest-risk page in this set — without their blast count changing at all.

That is disorienting in a specific way. Nothing about the illness has altered in the last week; what has altered is what is known about it.

The practical shape of treatment is the higher-risk one: drug treatment, transfusion support, monitoring, and a real decision about whether a transplant is right. That decision is harder here than almost anywhere else in this library, because the disease is more aggressive and the treatment is longer.

If a transplant does go ahead, it is worth knowing in advance that further treatment afterward is recommended rather than exceptional for this subtype. Being told about more treatment after a transplant is not a sign that something has gone wrong.

A donor route exists here and is recommended for people who are eligible. EBMT grades a transplant as standard of care for high and very high risk MDS, and grades it identically from a matched sibling, a well-matched unrelated donor and a mismatched alternative donor. A stranger is not a lesser option.

It is also the subtype where over-promising would do the most harm, so: a transplant is recommended, and it is a harder and longer road here than the phrase “a donor could cure them” suggests. The same guidance that recommends it also recommends further treatment afterward.

That is not a reason to withhold the information. It is a reason to give it accurately, to a reader who is likely making one of the hardest decisions in this whole library.